JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB142097

Capecitabine, DNA synthesis inhibitor

Be the first to review this product! Submit a review

|

(3 Publications)

MW 359.35 Da, Purity >99%. Selective, novel oral fluoropyrimidine carbamate. Prodrug of 5-Fluorouracil (ab142387). Anticancer agent. Active in vitro and in vivo.

View Alternative Names

IMD42, MGC129539, NR1F3, Nuclear receptor ROR-gamma, Nuclear receptor RZR-gamma, Nuclear receptor subfamily 1 group F member 3, RAR related orphan nuclear receptor variant 2, RAR related orphan receptor C, isoform a, RAR related orphan receptor gamma, RAR-related orphan receptor C, RORG_HUMAN, RZR GAMMA, RZRG, Retinoic acid binding receptor gamma, Retinoid-related orphan receptor-gamma, Rorc, TOR

Key facts

CAS number

154361-50-9

Purity

>99%

Form

Solid

form

Molecular weight

359.35 Da

Molecular formula

C<sub>1</sub><sub>5</sub>H<sub>2</sub><sub>2</sub>FN<sub>3</sub>O<sub>6</sub>

PubChem

60953

Nature

Synthetic

Solubility

Soluble in DMSO to 100 mM

Soluble in ethanol to 100 mM

Biochemical name

Capecitabine

Biological description

Selective, novel oral fluoropyrimidine carbamate. Prodrug of 5-Fluorouracil (ab142387). Anticancer agent. Active in vitro and in vivo.

Canonical smiles

CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O

Isomeric smiles

CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@H]2[C@@H]([C@@H]([C@H](O2)C)O)O

InChi

InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1

InChiKey

GAGWJHPBXLXJQN-UORFTKCHSA-N

IUPAC Name

pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate

Product details

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate long-term storage conditions
-20°C
Storage information
Store under desiccating conditions

Product protocols

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

Oncotarget 7:7715-31 PubMed26735339

2016

Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.

Applications

Unspecified application

Species

Unspecified reactive species

Manuela Terranova-Barberio,Maria Serena Roca,Andrea Ilaria Zotti,Alessandra Leone,Francesca Bruzzese,Carlo Vitagliano,Giosuè Scogliamiglio,Domenico Russo,Giovanni D'Angelo,Renato Franco,Alfredo Budillon,Elena Di Gennaro

Cancer letters 349:128-35 PubMed24746899

2014

Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Hailong Shi,Jinling Jiang,Jun Ji,Min Shi,Qu Cai,Xuehua Chen,Yingyan Yu,Bingya Liu,Zhenggang Zhu,Jun Zhang

European journal of cancer (Oxford, England : 1990) 34:1274-81 PubMed9849491

1998

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.

Applications

Unspecified application

Species

Unspecified reactive species

M Miwa,M Ura,M Nishida,N Sawada,T Ishikawa,K Mori,N Shimma,I Umeda,H Ishitsuka
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com